FK 224

tachykinin receptor antagonist; structure given in first source

Also Known As:

FK-224; FK224; N-(N(2)-(N-(N-(N-(2,3-didehydro-N-methyl-N-(N-(3-(2-pentylphenyl)-propionyl)-L-threonyl)tyrosyl-L-leucyl)-D-phenylalanyl)-L-allo-threonyl)-L-asparaginyl))-L-serine-epsilon-lactone

Networked: 14 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - FK 224: 14
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - FK 224: 14

Experts

1.	Fujimura, Masaki: 1 article (12/2004)
2.	Nakao, Shinji: 1 article (12/2004)
3.	Nishitsuji, Masaru: 1 article (12/2004)
4.	Oribe, Yoshitaka: 1 article (12/2004)
5.	Hirano, Kuniyoshi: 1 article (02/2002)
6.	Iijima, Hiroaki: 1 article (02/2002)
7.	Ishii, Yukio: 1 article (02/2002)
8.	Masuyama, Kuniko: 1 article (02/2002)
9.	Morishima, Yuko: 1 article (02/2002)
10.	Nomura, Akihiro: 1 article (02/2002)

Related Diseases

1.	Inflammation (Inflammations) 12/01/1994 - "However, the similar microvascular distributions of NK,binding sites in human and guinea pig lung suggest that the selective tachykinin receptor antagonistsFK888 and FK224 may be useful in the management of airway inflammation in man." 12/01/1997 - "The effects of a specific tachykinin receptor antagonist FK-224 on ozone-induced airway hyperresponsiveness and inflammation."
2.	Asthma (Bronchial Asthma) 06/01/1996 - "In this study we examined the reproducibility of the NKA challenge and the effect of inhaled FK224 on NKA-induced bronchoconstriction in 10 patients with stable asthma. " 11/21/1992 - "In a double-blind, placebo-controlled, crossover trial, ten subjects with stable asthma were given FK-224 (4 mg) or placebo by inhalation 20 min before challenge with bradykinin (0-1250 micrograms/ml, five breaths of each concentration) given with 5 min intervals. " 03/01/1993 - " of selective tachykinin receptor antagonists will be important in understanding the involvement of tachykinins in airway physiology and pathophysiology, whereas potent dual tachykinin receptor antagonists such as FK224 may have greater therapeutic potential in certain airway diseases in which tachykinins have been implicated in pathogenesis, including asthma and chronic bronchitis associated with cigarette smoking."
3.	Edema (Dropsy) 07/01/1992 - "The effects of FK224 on airway constriction and airway edema induced by NKs and nerve stimulation have been investigated in guinea pigs. " 07/01/1992 - "Effects of FK224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerve stimulation in guinea pigs." 07/01/1992 - "FK224 also inhibited SP (1.3 micrograms kg-1)-, NKA (11 micrograms kg-1)- and capsaicin (100 micrograms kg-1)-induced airway edema with ED50 values of 0.14 mg kg-1, 0.29 mg kg-1 and 0.30 mg kg-1, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)" 11/01/1993 - "Posttreatment with intravenous CP-96,345 and intravenous FK224 failed to reduce the level of thermal hyperesthesia or paw edema, and intrathecal injections, either pre- or posttreatment, had no effect on thermal hyperesthesia or paw edema. " 11/01/1993 - "In the pretreatment study, both intravenous CP-96,345 and intravenous FK224 blocked the development of thermal hyperesthesia and reduced paw edema in a dose-dependent manner 2 h after the carrageenan injection. "
4.	Respiratory Tract Diseases (Respiratory Tract Disease) 09/01/1995 - "FK224 and FK888 are now undergoing clinical studies to test the effectiveness of a NK antagonist in human respiratory diseases."
5.	Hyperesthesia 11/01/1993 - "Posttreatment with intravenous CP-96,345 and intravenous FK224 failed to reduce the level of thermal hyperesthesia or paw edema, and intrathecal injections, either pre- or posttreatment, had no effect on thermal hyperesthesia or paw edema. " 11/01/1993 - "In the pretreatment study, both intravenous CP-96,345 and intravenous FK224 blocked the development of thermal hyperesthesia and reduced paw edema in a dose-dependent manner 2 h after the carrageenan injection. " 11/01/1993 - "In the current study, the authors examined the role of NK1 and NK2 receptors on the thermal hyperesthesia evoked by injection of carrageenan into the rat paw using FK224, a cyclopeptide NK1 and NK2 antagonist, and CP-96,345, a nonpeptide NK1 antagonist. " 11/01/1993 - "Effects of FK224, a novel cyclopeptide NK1 and NK2 antagonist, and CP-96,345, a nonpeptide NK1 antagonist, on development and maintenance of thermal hyperesthesia evoked by carrageenan injection in the rat paw."

Related Drugs and Biologics

1.	Tachykinin Receptors (Tachykinin Receptor)
2.	FK 888
3.	Bradykinin
4.	Cyclic Peptides
5.	Carrageenan
6.	Tachykinins
7.	Capsaicin (Zostrix)
8.	Citric Acid (Citrate)
9.	Neurokinin-1 Receptors (Neurokinin 1 Receptor)
10.	Substance P

Related Therapies and Procedures

1.	Spinal Injections